Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
Patents for A61P 31 - Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics (179,784)
10/2005
10/27/2005US20050239906 Use of resveratrol for the preparation of a medicament useful for the treatment of influenza virus infections
10/27/2005US20050239835 controlling weight gain; 1-(1-amino-2-phenylethylcarbonyl)-4-cyclohexylpiperidine compounds
10/27/2005US20050239827 N-(4-(2,2-difluoro-benzo(1,3)dioxol-5-ylcarbamoyl)-3-hydroxy-phenyl)-4,6-Bis-((3R,5S)-3,5-diamino-piperidin-1-yl)-(1,3,5)triazine-2-amine for example; Gram-positive and Gram-negative strains; retains potency against common antibiotic resistant strains
10/27/2005US20050239824 Triple monoamine reuptake inhibitors for the treatment of chronic pain
10/27/2005US20050239821 Viral inhibitors
10/27/2005US20050239819 4-Oxoquinoline compounds and utilization thereof as hiv integrase inhibitors
10/27/2005US20050239804 Method for improved chemical synthesis of guanidinium alkaloids
10/27/2005US20050239771 Respiratory syncytial virus replication inhibitors
10/27/2005US20050239737 Identification of molecular interaction sites in RNA for novel drug discovery
10/27/2005US20050239732 Immunostimulatory nucleic acid molecules
10/27/2005US20050239720 Combination of an agent that attenuates topoisomerase 1 activity and an agent that inhibits heat shock protein 90 for use in chemotherapy
10/27/2005US20050239699 Remedy for infections
10/27/2005US20050239693 Template-fixed peptidomimetics with antibacterial activity
10/27/2005US20050239691 Cross-linked glycopeptide - cephalosporin antibiotics
10/27/2005US20050239690 Intermediate for preparing glycopeptide derivatives
10/27/2005US20050239202 Methods and compositions for inhibiting the function of polynucleotide sequences
10/27/2005US20050239201 Methods of inducing differentiation of stem cells into a specific cell lineage
10/27/2005US20050239170 Alpha-MSH related compounds and methods of use
10/27/2005US20050239157 High throughput screen for inhibitors of fatty acid biosynthesis in bacteria
10/27/2005US20050239141 Modified antibody variable domains
10/27/2005US20050239131 Interactive system for presenting and eliminating substances
10/27/2005US20050239099 27 human secreted proteins
10/27/2005US20050239054 Drug screening compounds having esterified phosphonate or carboxyl groups with novel enzyme GS-7340 Ester Hydrolase and identifying the compound as a suitable prodrug by the formation of a phosphonic acid or carboxylic acid; candidate compounds
10/27/2005US20050238740 Use of mastic and its components for the control of microbial infections
10/27/2005US20050238706 Pharmaceutically active lipid based formulation of SN-38
10/27/2005US20050238670 Immunology response intensifiers; administering a bacterial lysate, for inducing an immune response to Staphylococcus aureus infections
10/27/2005US20050238660 Cpg formulations and related methods
10/27/2005US20050238656 Recombinant vesiculoviruses and their uses
10/27/2005US20050238655 Antiviral activity from medicinal mushrooms
10/27/2005US20050238637 Vectors for molecule delivery to CD11b expressing cells
10/27/2005US20050238635 Use of hyrogen peroxide producting enzyme for treatment of otitis media
10/27/2005US20050238634 Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
10/27/2005US20050238578 Administering anticarcinogenic agent and chelate complex of macrocyclic aminophosphonic acid and radionuclide such as samarium ethylenediaminetetramethylenephosphonic acid (EDTMP) to replace total body irradiation;antiproliferative agents; autoimmune, infectious, metabolic or genetic disorders
10/27/2005DE102004016683A1 Dauerhaft geschäumte Zusammensetzung Permanently foamed composition
10/27/2005CA2564878A1 Therapeutic heparins and their binding to interleukins 4 and 5, and pecam-1
10/27/2005CA2563689A1 Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
10/27/2005CA2562846A1 Sulphur-linked imidazole compounds for the treament of hiv
10/26/2005EP1589108A2 Methods and reagents for vaccination which generate a CD8 T cell immune response
10/26/2005EP1589107A1 Immunoglobulins devoid of light chains
10/26/2005EP1589099A1 Immortalized natural killer cell line
10/26/2005EP1589031A2 Production of polyketides and other natural products
10/26/2005EP1589028A2 Modified oligonucleotides, their preparation and their use
10/26/2005EP1589007A2 5-membered heterocycle derivatives, production thereof and their use as medicaments
10/26/2005EP1588715A1 Agent improving proton-driven transporter-mediated absorption in digestive tract and process for producing the same
10/26/2005EP1588714A2 Adjuvant systems and vaccines
10/26/2005EP1588713A1 Production of human papillomavirus HBV-11 capsid protein L1 and virus-like particles
10/26/2005EP1588712A1 Modulators of regulatory proteins
10/26/2005EP1588702A1 Azalide antibiotics for the topical treatment or prevention of ocular infections
10/26/2005EP1588692A1 Durable foamed composition
10/26/2005EP1587926A2 Lipophilic derivatives of double-stranded ribonucleic acid
10/26/2005EP1587838A2 Therapeutic polypeptides, homologues thereof, fragments thereof and for use in modulating platelet-mediated aggregation
10/26/2005EP1587830A1 Peptide inhibitors of toxins derived from ll-37
10/26/2005EP1587825A2 Antigen imitating extracellular areas of membrane proteins of type iii produced from intracellular pathogenic micro-organisms, derived conformational antibodies and the use thereof
10/26/2005EP1587787A1 Viral polymerase inhibitors
10/26/2005EP1587585A1 Acylsulfonamide compounds as inhibitors of rna-dependent rna (viral) polymerases
10/26/2005EP1587539A1 Antimicrobial composition for local use on mucosal membranes and skin
10/26/2005EP1587538A1 Mucosal meningococcal vaccines
10/26/2005EP1587521A1 Bioavailability enhancing activity of carum carvi extracts and fractions thereof
10/26/2005EP1587520A1 Bacteriophage for the treatment of bacterial biofilms
10/26/2005EP1587507A1 A method of treatment or prophylaxis of symptoms of herpes viral infection
10/26/2005EP1587482A2 Anti-inflammatory compositions and uses thereof
10/26/2005EP1587480A2 Polyhydroxylated pyrrolizidine
10/26/2005EP1587473A2 Thiosemicarbazones as anti-virals and immunopotentiators
10/26/2005EP1341766B1 Imidazolone derivatives for the treatment of viral diseases
10/26/2005EP1299406B1 Curcumin derivatives with improved water solubility compared to curcumin and medicaments containing the same
10/26/2005EP1163234B1 Pharmaceutical formulations with improved aqueous solubility
10/26/2005EP1151010B1 Human polyclonal antibodies from transgenic nonhuman animals
10/26/2005EP1087778B1 Use of peg-ifn-alpha and ribavirin for the treatment of chronic hepatitis c
10/26/2005EP1073415B1 Pharmaceutical compositions capable of being gelled
10/26/2005EP1037640B1 Administration of products of the 5-lipoxygenase metabolic pathway to enhance antimicrobial defense
10/26/2005EP0973727B1 Activated iododerivatives for the treatment of cancer and aids
10/26/2005EP0910428B1 Photopheresis treatment of chronic hcv infections
10/26/2005EP0876150B1 Non-toxic mutants of pathogenic gram-negative bacteria
10/26/2005EP0762880B1 Retroviral protease inhibitor combinations
10/26/2005CN1688707A Tiacumicin production
10/26/2005CN1688605A Novel immunogenic lipopeptides comprising T-helper and cytotoxic T lymphocyte (CTL) epitopes
10/26/2005CN1688600A Template-fixed peptidomimetics with antibacterial activity
10/26/2005CN1688589A Beta-lactamase inhibitor prodrug
10/26/2005CN1688586A Broadspectrum substituted oxindole sulfonamide HIV protease inhibitors
10/26/2005CN1688580A Derivatives of 2-trifluormethyl-6-aminopurine as phosphodiesterase 4 inhibitors
10/26/2005CN1688578A Phosphodiesterase 4 inhibitors
10/26/2005CN1688577A Triazaspiro [5.5] undecane derivatives and drugs comprising the same as the active ingredient
10/26/2005CN1688548A Process for preparing quinolin antibiotic intermediates
10/26/2005CN1688543A Furanone derivatives and methods of making same
10/26/2005CN1688336A Mycoplasma gallisepticum formulation, its mycoplasma strain k5054 and its application
10/26/2005CN1688335A Continuous cell line for the production of vaccines
10/26/2005CN1688316A Prophylaxis and treatment of infectious diseases
10/26/2005CN1688306A Use of posaconazole for the treatment of fungal infections
10/26/2005CN1224708C i (Neisseria meningitidis) antigens
10/26/2005CN1224707C Intracellular isoform of the interleukin-1 receptor antagonist
10/26/2005CN1224704C Preparing method for recombinant chBJSTWO protein
10/26/2005CN1224623C 1-phenysulfonyl-1, 3-dihydro-2H-indole-2-one derivatives, their preparation and their therapeutic use
10/26/2005CN1224612C Acetylenic sulfonamide thiol TACE inhibitors
10/26/2005CN1224479C Mathod for preparing micro powder containing anti-agglomerated nanometer silver, micro powder produced by the mathod
10/26/2005CN1224423C Pharmaceutical composition improved in peroral absorbability
10/26/2005CN1224422C Vaccines comprising interleukin-12 and herpes simplex viral antigen
10/26/2005CN1224419C Orally administered peptides to ameliorate a therosclerosis
10/26/2005CN1224411C Freeze-dried powder injection of Corydalis thalictrifolia franch for curing hepatitis, large dise transfusion medicine preparation method
10/26/2005CN1224406C Medical ointment for treating athlete's foot
10/25/2005US6958383 Streptogramin derivatives, preparation method and compositions containing same
1 ... 929 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 ... 1798